Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Jazz Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.0%. By the end of trading, Jazz Pharmaceuticals fell $1.16 (-1.0%) to $113.34 on average volume. Throughout the day, 949,629 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 719,100 shares. The stock ranged in price between $111.14-$116.40 after having opened the day at $115.09 as compared to the previous trading day's close of $114.50. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 38.6%,

Conatus Pharmaceuticals



), down 11.9%,

Amarin Corporation



), down 11.5% and

Oncolytics Biotech



), down 8.3%.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $6.5 billion and is part of the health care sector. The company has a P/E ratio of 20.9, above the S&P 500 P/E ratio of 17.7. Shares are up 110.2% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

Jazz Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

Ariad Pharmaceuticals

TheStreet Recommends



), up 35.5%,

Galena Biopharma



), up 14.6%,




), up 14.6% and

Cardiome Pharma Corporation



), up 14.4% , were all gainers within the drugs industry with

Eli Lilly and Company



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.